Colorectal Cancer Prognosis is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study.

BACKGROUND

We investigated the associations between v-Raf murine sarcoma viral oncogene homolog B1 (, henceforth ) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog ) mutations and colorectal cancer (CRC) prognosis, using The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GSE39582) datasets.

MATERIALS AND METHODS

The effects of and mutations on overall survival (OS) and disease-free survival (DFS) of CRC were evaluated.

RESULTS

The mutational status of and genes was not associated with overall survival (OS) or DFS of the CRC patients drawn from the TCGA database. The 3-year OS and DFS rates of the mutation (+) vs. mutation (-) groups were 92.6% vs. 90.4% and 79.7% vs. 68.4%, respectively. The 3-year OS and DFS rates of the mutation (+) vs. mutation (-) groups were 90.4% vs. 90.5% and 65.3% vs. 73.5%, respectively. In stage II patients, however, the 3-year OS rate was lower in the mutation (+) group than in the mutation (-) group (85.5% vs. 97.7%, <0.001). The mutational status of genes of 497 CRC patients drawn from the GSE39582 database was not associated with OS or DFS. The 3-year OS and DFS rates of mutation (+) vs. mutation (-) groups were 75.7% vs. 78.9% and 73.6% vs. 71.1%, respectively. However, mutational status had an effect on 3-year OS rate (71.9% mutation (+) vs. 83% mutation (-), = 0.05) and DFS rate (66.3% mutation (+) vs. 74.6% mutation (-), = 0.013).

CONCLUSIONS

We found no consistent association between the mutational status of nor and the OS and DFS of CRC patients from the TCGA and GSE39582 databases. Studies with longer-term records and larger patient numbers may be necessary to expound the influence of and mutations on the outcomes of CRC.